In a New York Times column this week, the Pennsylvania Democrat shared his experience taking Mounjaro while advocating for ...

Fetterman appealed to President Trump and Health and Human Services Secretary Robert F. Kennedy Jr. personally.

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

Sen. John Fetterman (D-Pa.) on Wednesday called on the Trump administration to back a Biden-era rule that would expand access ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Medicare Advantage plans are squeezing billions out of the federal government by billing more for patient care, a new study ...

CMS has released its final rule for Medicare Advantage and Part D for 2026, introducing several regulatory changes aimed at ...

In November, President Biden set out to change that with a new rule that would drastically expand access to this type of ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

The Trump administration reversed a Biden-era proposal for Medicare coverage of anti-obesity treatments. But on Monday, HHS ...

Due to current legislation, Medicare Part D or C plans may only cover Zepbound for obstructive sleep apnea. However, the Centers for Medicare & Medicaid Services may expand weight loss medication ...